Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7454284 | 0.92 | F10 (0.39) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6744826 | 0.86 | CA1 (0.46) | PTGS1PTGS2 | |
| SCHEMBL6747452 | 0.81 | CA9 (0.43) | PTGS1PTGS2 | |
| SCHEMBL7456268 | 0.77 | F10 (0.38) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8633277 | 0.76 | PTGS2 (0.50) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8632274 | 0.74 | F10 (0.40) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8628225 | 0.73 | F10 (0.41) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8632661 | 0.73 | PTGS2 (0.44) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8627604 | 0.72 | PTGS2 (0.41) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8631834 | 0.72 | PTGS2 (0.46) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696477-B2 | AS ANTIINFLAMMATORY AGENTS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | claimed |
| US-20020058810-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2002-05-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058810-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | F10 2317/4885F2 898/4885PRSS1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.